Table 4 Main active substances affected by Pediatric Pharmaceutical Interventions by age group (n ≥ 4)

≤ 3 years

105

Paracetamol

10

9.6

[3.9 − 15.1%]

Compliance problem

Camphor/turpentine/levomenthol/eucalyptus essential oil

8

7.7

[2.5 − 12.7%]

Physio-pathological contradication

Oxomemazine

7

6.7

[1.9 − 11.4%]

Physio-pathological contradication

Racecadotril

7

6.7

[1.9 − 11.4%]

Non-accordance with legislation

Diosmectite

6

5.8

[1.3 − 10.2%]

Ibuprofen

5

4.8

[1.3 − 10.2%]

Metopimazine

5

4.8

[0.7 − 8.8%]

3–17 years

181

Ibuprofen

17

9.3

[5.1 − 13.6%]

Physio-pathological contradication

Oxomemazine

11

6.0

[2.6 − 9.6%]

Non indication

Paracetamol

11

6.0

[2.6 − 9.6%]

Compliance problem

Camphor/turpentine/levomenthol/eucalyptus essential oil

9

4.9

[1.8 − 8.1%]

Physio-pathological contradication

Metopimazine

8

4.4

[1.4 − 7.4%]

Acide ascorbique/paracetamol/ pheniramine maleate

7

3.8

[1.1 − 6.7%]

Racecadotril

7

3.8

[1.1 − 6.7%]